Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does TOCILIZUMAB Cause Magnetic resonance imaging head abnormal? 10 Reports in FDA Database

Grow Your Own Natural Pharmacy at Home

Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.

Get the Kit

According to the FDA Adverse Event Reporting System (FAERS), 10 reports of Magnetic resonance imaging head abnormal have been filed in association with TOCILIZUMAB (Tocilizumab-anoh). This represents 0.0% of all adverse event reports for TOCILIZUMAB.

10
Reports of Magnetic resonance imaging head abnormal with TOCILIZUMAB
0.0%
of all TOCILIZUMAB reports
0
Deaths
7
Hospitalizations

How Dangerous Is Magnetic resonance imaging head abnormal From TOCILIZUMAB?

Of the 10 reports, 7 (70.0%) required hospitalization.

Is Magnetic resonance imaging head abnormal Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for TOCILIZUMAB. However, 10 reports have been filed with the FAERS database.

What Other Side Effects Does TOCILIZUMAB Cause?

Drug ineffective (32,342) Rheumatoid arthritis (20,652) Pain (18,384) Off label use (18,256) Arthralgia (15,536) Joint swelling (14,831) Fatigue (13,802) Rash (12,327) Drug intolerance (11,952) Contraindicated product administered (11,547)

What Other Drugs Cause Magnetic resonance imaging head abnormal?

VIGABATRIN (187) OCRELIZUMAB (72) ADALIMUMAB (32) MYCOPHENOLATE MOFETIL (31) PREDNISOLONE (25) DEXAMETHASONE (24) CORTICOTROPIN (21) PREDNISONE (21) METHOTREXATE (17) RITUXIMAB (17)

Which TOCILIZUMAB Alternatives Have Lower Magnetic resonance imaging head abnormal Risk?

TOCILIZUMAB vs TOCILIZUMAB-AAZG TOCILIZUMAB vs TOCOPHEROL TOCILIZUMAB vs TOFACITINIB TOCILIZUMAB vs TOFERSEN TOCILIZUMAB vs TOLNAFTATE

Related Pages

TOCILIZUMAB Full Profile All Magnetic resonance imaging head abnormal Reports All Drugs Causing Magnetic resonance imaging head abnormal TOCILIZUMAB Demographics